A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Source: View publication →
In the phase 3 CLARITY trial, short-course oral cladribine significantly reduced the annualized relapse rate, improved relapse-free survival, and delayed disability progression compared to placebo in patients with relapsing-remitting multiple sclerosis, but carried an increased risk of lymphocytopenia.
Key Findings
Study Design
Study Limitations
Clinical Significance
The CLARITY trial demonstrated that short-course oral cladribine is highly efficacious in reducing clinical relapses, MRI lesion activity, and disability progression in relapsing-remitting multiple sclerosis. Its convenient, low-burden oral administration schedule (dosed over just 8 to 20 days per year) offered a paradigm shift from continuously administered parenteral therapies. Despite initial regulatory hurdles concerning malignancy risks, the robust efficacy and manageable safety profile established by CLARITY ultimately paved the way for cladribine's approval as a highly active immune reconstitution therapy for MS.
Historical Context
At the time of the CLARITY trial's publication in 2010, the standard of care for relapsing-remitting multiple sclerosis primarily involved continuous, self-injectable immunomodulators (interferons and glatiramer acetate), which suffered from injection fatigue and compliance issues. The prospect of highly effective oral agents was a major unmet need. Cladribine, a purine antimetabolite originally used for hairy cell leukemia, acts as an immune reconstitution therapy by selectively depleting B and T lymphocytes with subsequent repopulation. Following CLARITY, regulatory agencies initially rejected oral cladribine due to a slight imbalance in malignancies. However, further long-term safety data from the CLARITY extension and PREMIERE registry clarified its safety profile, leading to the EMA's approval of Mavenclad in 2017 and the FDA's approval in 2019 for highly active relapsing MS.
Guided Discussion
High-yield insights from every perspective
What is the biochemical mechanism of action of cladribine, and why does it selectively cause lymphocytopenia without causing severe broad-spectrum myelosuppression?
Key Response
Cladribine is a synthetic purine nucleoside analog that is resistant to degradation by adenosine deaminase. Lymphocytes uniquely possess high levels of deoxycytidine kinase (which phosphorylates and activates cladribine) and low levels of 5'-nucleotidase (which normally degrades it). This enzymatic imbalance causes the active triphosphate form to selectively accumulate in B and T lymphocytes, leading to DNA strand breaks and targeted apoptosis, largely sparing other hematopoietic lineages.
Given the high incidence of severe lymphocytopenia observed in the CLARITY trial, what specific baseline screening and longitudinal monitoring protocols must a clinician implement when initiating and managing a patient on oral cladribine?
Key Response
Prior to initiation, clinicians must obtain a baseline complete blood count (specifically checking the absolute lymphocyte count), screen for latent infections (tuberculosis, hepatitis B and C, HIV), and ensure varicella-zoster virus (VZV) immunity. Longitudinally, lymphocyte counts must be monitored at months 2 and 6 after each treatment course; recovery to at least Grade 1 (greater than 800 cells per cubic millimeter) is required before administering the second year's treatment course to prevent opportunistic infections.
Oral cladribine is classified as an immune reconstitution therapy (IRT) rather than a chronic continuous immunosuppressant. If a patient experiences a severe clinical relapse 18 months into the two-year CLARITY dosing protocol, how does the IRT concept influence your decision regarding whether to re-dose, bridge, or switch to a different high-efficacy disease-modifying therapy (DMT)?
Key Response
As an IRT, cladribine's therapeutic effect relies on the qualitative resetting of the adaptive immune system during lymphocyte repopulation, and its effects can persist long after the drug is cleared. A relapse at 18 months might represent transient breakthrough disease during repopulation or true treatment failure. Because cumulative dosing beyond the standard 2-year regimen increases the risk of prolonged profound immunosuppression and potential malignancy, fellows must carefully sequence to another therapy (e.g., anti-CD20 monoclonal antibodies) while managing the overlapping periods of lymphopenia to avoid catastrophic infectious complications.
The CLARITY trial initially faced regulatory hurdles due to a slight numerical imbalance in malignancies in the cladribine arms compared to placebo. How do you balance this potential risk against the convenience of a short-course oral regimen during shared decision-making with a patient who has highly active relapsing-remitting MS?
Key Response
Attendings must contextualize the malignancy signal by explaining that while the absolute risk is low and long-term registry data has provided some reassurance, the drug is a potent antineoplastic agent. The discussion should contrast the profound convenience and high efficacy of a few treatment days per year against the irreversible nature of pulsed immunosuppression and the stringent need for continuous vigilance. It is often positioned for patients who have failed other DMTs or place a high value on avoiding frequent infusions or injections, provided they accept the required intensive laboratory monitoring.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In longitudinal MS trials like CLARITY, adverse events such as severe lymphocytopenia often lead to higher rates of treatment discontinuation in the active arm. How might informative censoring due to adverse events bias the estimation of the primary endpoint (annualized relapse rate), and what statistical modeling approaches should be utilized to test the robustness of the findings?
Key Response
If patients who drop out due to drug toxicity differ systematically in their underlying disease severity (e.g., they might have had higher or lower relapse rates if they had stayed in the trial), assuming missing-at-random (MAR) in standard Poisson or negative binomial regression models will yield biased treatment effect estimates. Methodologists should implement pattern-mixture models, tipping point analyses, or joint models for longitudinal data and survival to evaluate how sensitive the annualized relapse rate results are under missing-not-at-random (MNAR) assumptions.
The CLARITY trial utilized a placebo control in patients with relapsing-remitting MS, which allows for clean safety signal detection but raises questions about comparative efficacy. From an editorial standpoint, how do you evaluate the ethical justification and clinical relevance of publishing a placebo-controlled trial in an era where multiple established, active disease-modifying therapies exist?
Key Response
A critical reviewer would flag that while a placebo arm is optimal for isolating the specific risks of cladribine (like the true incidence of lymphocytopenia and malignancies), it deprives the control group of standard-of-care treatments, raising ethical concerns in MS where irreversible neurologic damage occurs. Furthermore, an editor must consider that a lack of an active comparator (such as interferon beta or an anti-CD20 agent) limits the ability of clinicians to definitively place cladribine within the modern, highly crowded MS treatment algorithm.
Current AAN and ECTRIMS guidelines stratify the use of MS therapies based on disease activity and safety profiles. Based on the robust efficacy yet significant lymphocytopenia risk demonstrated in the CLARITY trial, should oral cladribine be recommended as a universal first-line agent, or restricted to an escalation strategy for highly active disease, and what level of evidence dictates this placement?
Key Response
While the CLARITY trial provides Class I evidence of high efficacy in reducing relapses and disability progression, guideline committees do not recommend cladribine as a universal first-line agent. Due to its safety profile, including prolonged severe lymphocytopenia and the need to mitigate opportunistic infection and malignancy risks, current guidelines typically restrict its use as a second-line or escalation therapy for patients with highly active MS, or for those who have had an inadequate response to or cannot tolerate alternate MS medications.
Clinical Landscape
Noteworthy Related Trials
FREEDOMS Trial
Tested
Fingolimod 0.5 mg or 1.25 mg daily
Population
Patients with relapsing-remitting multiple sclerosis
Comparator
Placebo
Endpoint
Annualized relapse rate
TEMSO Trial
Tested
Teriflunomide 7 mg or 14 mg daily
Population
Patients with relapsing-remitting multiple sclerosis
Comparator
Placebo
Endpoint
Annualized relapse rate
DEFINE Trial
Tested
Dimethyl fumarate (BG-12) 240 mg twice or thrice daily
Population
Patients with relapsing-remitting multiple sclerosis
Comparator
Placebo
Endpoint
Proportion of patients relapsing at 2 years
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis